SEARCH

SEARCH BY CITATION

References

  • 1
    Berry SL, Coffey DS, Walsh PC, Ewing LL. The development of human benign prostatic hyperplasia with age. J Urol 1984; 132: 474 9
  • 2
    Bosch JL, Hop WC, Kirkels WJ et al. The International Prostate Symptom Score in a community-based sample of men between 55 and 74 years of age: Prevalence and correlation of symptoms with age, prostate volume, flow rate and residual urine volume. Br J Urol 1995; 75: 622 30
  • 3
    Kortt MA & Bootman JL. The economics of benign prostatic hyperplasia: a literature review. Clin Ther 1996; 18: 1227 41
  • 4
    Oesterling JE. Benign prostatic hyperplasia. Medical and minimally invasive treatment options. N Engl J Med 1995; 332: 99 109
  • 5
    Wilt TJ, Ishani A, Stark G, MacDonald R, Lau J, Mulrow C. Saw palmetto extracts for treatment of benign prostatic hyperplasia: a systematic review. JAMA 1998; 280: 1604 9
  • 6
    Schmitz W. Urologika. In SchwabeU, PaffrathD, eds. Arzneimittel Verdungs – Report 87, Stuttgart: Fischer G, 1987: 365 73
  • 7
    Marwick C. Growing use of medicinal botanicals forces assessment by drug regulators. JAMA 1995; 273: 607 9
  • 8
    Buck AC. Phytotherapy for the prostate. Br J Urol 1996; 78: 325 6
  • 9
    Ito R, Ishii M, Yamashita S et al. Antiprostatic hypertrophic action of Cernilton pollen-extract. Pharmacometrics 1986; 31: 1 11
  • 10
    Kimura M, Kimura I, Nakase K, Sonobe T, Mori E. Micturition activity of pollen extract: contractile effects on bladder and inhibitory effects on urethral smooth muscle of mouse and pig. Planta Med 1986; 2: 148 51
  • 11
    Nakase S, Takenaka K, Hamanaka T, Kimura M. Effects of Cernilton pollen-extract on the urethral smooth muscle and diaphragmatic neuromuscular specimen. Folio Pharmacol Japan 1988; 91: 385 92
  • 12
    Dickersin K, Scherer R, Lefebvre C. Identifying relevant studies for systematic reviews. Br Med J 1996; 312: 944 7
  • 13
    Rohrborn C & Rugendorff EW. Uroflow index – a formula for simplifying examination and the comparison of uroflow measurement curves in practice. Z Urol Nephrol 1983; 76: 721 4
  • 14
    Schulz KF, Chalmers I, Hayes RJ, Altman DG. Empirical evidence of bias: dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA 1995; 273: 408 12
  • 15
    Update Software. RevMan, Version 3.0 For Windows Oxford: Update Software 1996
  • 16
    Lau J. Meta-Analyst, Version 0.99. Boston: New England Medical Center 1996
  • 17
    Laird N & Mosteller F. Some statistical methods for combining experiment results. Int J Tech Assess Health Care 1990; 6: 5 30
  • 18
    Lavori PW. Clinical trials in psychiatry: should protocol deviation censor patient data? Neuropsychopharmacology 1992; 6: 39 63
  • 19
    Becker H & Ebeling L. Konservative therapie der benignen prostata-hyperplasie (BPH) mit Cernilton®N: ergebnisse einer plazebokontrollierten doppleblindstudie. Urologe B 1988; 28: 301 6
  • 20
    Buck AC, Cox R, Rees RWM, Ebeling L, John A. Treatment of outflow tract obstruction due to benign prostatic hyperplasia with the pollen-extract, Cernilton: a double-blind, placebo-controlled study. Br J Urol 1990; 66: 398 04
  • 21
    Dutkiewicz S. Usefulness of Cernilton in the treatment of benign prostatic hyperplasia. Int Urol Nephrol 1996; 28: 49 53
  • 22
    Maekawa M, Kishimoto T, Yasumoto R et al. Clinical evaluation of Cernilton on benign prostatic hypertrophy: a multiple center double-blind study with Paraprost. Hinyo Kiyo 1981; 27: 317 26
  • 23
    Hayashi J, Mitsui H, Yamakawa G et al. Clinical evaluation of Cernilton in benign prostatic hypertrophy. Hinyo Kiyo 1986; 32: 135 41
  • 24
    Yasumoto R, Kawanishi H, Tsujino T et al. Clinical evaluation of long-term treatment using Cernitin pollen extract with benign prostatic hyperplasia. Clin Ther 1995; 17: 82 7
  • 25
    Bero L & Drummond R. The Cochrane Collaboration: preparing, maintaining, and disseminating systematic reviews of the effects of health care. JAMA 1995; 274: 1935 8
  • 26
    Moher D, Jadad AR, Nichol G, Penman M, Tugwell P, Walsh S. Assessing the quality of a randomized controlled trials: an annotated bibliography of scales and checklists. Control Clin Trials 1995; 16: 62 73
  • 27
    Wilt TJ, MacDonald R, Ishani A. β-sitosterol for treatment of benign prostatic hyperplasia: a systematic review. BJU Int 1999; 83: 976 83
  • 28
    Barry MJ. A 73-year-old man with symptomatic benign prostatic hyperplasia. JAMA 1997; 278: 2178 84
  • 29
    McConnell JD, Bruskewitz RC, Walsh P et al. The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. N Engl J Med 1998; 338: 557 63
  • 30
    Chirikos T & Sanford E. Cost consequences of surveillance, medical management or surgery for benign prostatic hyperplasia. J Urol 1996; 155: 1311 6
  • 31
    Neal DE. Watchful waiting or drug therapy for benign prostatic hyperplasia? Lancet 1997; 350: 305 6